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Abstract
Background: The management of hyperglycaemia and associated cardiovascular risk factors in patients with type 2
diabetes mellitus (T2DM) may reduce diabetes-related complications. The strategy to broaden the knowledge base
of primary care professionals to improve health care has mainly been prompted by the current reality of limited
resources and access to specialized care. The main objective of this study is to assess the effectiveness of
comprehensive interventions focused on treatment intensification, decrease clinical inertia and reduce possible
barriers to treatment adherence in patients with poorly controlled diabetes in a primary care setting.
Methods: This is a two-phase mixed method study, whose aims are the development of complex interventions and
the assessment of their effectiveness. The main study outcome is a change in glycated haemoglobin (HbA1c) levels.
The INTEGRA study is divided into two phases. Phase 1: A qualitative study with a phenomenological approach using
semi-structured interviews with the objective of determining the factors related to the participants and health care
professionals that influence the development and implementation of a specific intervention strategy aimed at patients
with poor glycaemic control of T2DM in primary care. Phase 2: Exploratory intervention study to be conducted in
Primary Health Care Centres in Catalonia (Spain), including 3 specific health care areas.
The intervention study has two arms: Intervention Group 1 and 2. Each intervention group will recruit 216 participants
(the same as in the control group) between the ages of 30 and 80 years with deficient glycaemic control
(HbA1c > 9%). The control group will be established based on a randomized selection from the large SIDIAP
(Sistema d’Informació per al desenvolupament de la Investigació en Atenció Primària) database of patients
with comparable socio-demographic and clinical characteristics from the three provinces.
Discussion: This study is a comprehensive, pragmatic intervention based on glycaemic treatment intensification and
the control of other cardiovascular risk factors. It is also aimed at improving treatment adherence and reducing clinical
inertia, which could lead to improved glycaemic control and could likewise be feasible for implementation in
the actual clinical practice of primary care.
Trial registration: Clinicaltrials.gov. registration number. NCT02663245; January 25, 2016.
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Background
Type 2 diabetes mellitus (T2DM) is a chronic disease
with a significant socioeconomic impact due to its high
prevalence, the impact of associated complications, and
high rate of mortality [1]. The elevated costs associated
with the disease and its impact on patient quality of life
are currently the target of many health plans and gov-
ernment strategies. The benefits of proper control of
T2DM and the related cardiovascular risk factors, espe-
cially blood pressure and lipids, are widely accepted [2].
However, studies in Spain show that although evidence
of the improved care of T2DM patients exists, the thera-
peutic goals are often not achieved in real-life clinical
practice [3, 4].
A meta-analysis performed by Tricco et al. regarding
the evaluation of strategies used in clinical trials for the
improvement of quality procedures used in the manage-
ment of diabetes shows evidence that the most notable
improvements are observed when baseline levels of gly-
cated haemoglobin (HbA1c) are high, especially over 8%,
in diabetic patients [5]. This suggests that interventions
should focus on patients with poorer control. With re-
gard to strategies aimed at professionals and organiza-
tions that demonstrated efficacy, the most efficient were
feedback from the information obtained in audits, train-
ing of professionals, and organizational changes (such as
electronic records, clinical reminders, and case manage-
ment, in addition to financial incentives).
Treatment adherence and clinical inertia play an im-
portant role in cases of insufficient glycaemic control.
Therapeutic or clinical inertia is defined as the failure to
initiate or to intensify treatment when indicated [6],
thereby preventing or delaying the benefits of proper
control. In the DIAMOND [7] study conducted in Span-
ish primary care centres, mean HbA1c was 8.1% over an
average of 2.9 years, with values of > 7% before change,
when switching from monotherapy to combination ther-
apy was observed. Additionally, in an assessment of the
GEDAPS group carried out in Catalonia, clinical inertia
was detected in 33% of patients, and the mean HbA1c
level to perform the treatment change was 8.4%. [8].
Sometimes, clinical inertia is related to the non-com-
pliance of the patient [3, 9]. As seen in the Grant et al.
[10] study, interventions oriented to improve patient ad-
herence could consequently decrease clinical inertia.
However, there are few studies on interventions aimed
specifically at reducing clinical inertia.
Feedback to professionals is another possible key fac-
tor for improving clinical inertia. In an American study
[11, 12], feedback was given to the professionals on the
objectives achieved via alerts in the electronic records
and/or weekly short meetings between professionals. As
a result, treatment intensification increased from 35 to
52% in 3 years, and a significant improvement in HbA1c
values (in the group receiving feedback, mean HbA1c was
7.5% vs. 8.2% in the control group) was also observed.
However, in the Rochester study [13], although a reduc-
tion of more than 50% was observed in clinical inertia, this
did not translate into an improvement in the control pa-
rameters after one year. Therefore, although interventions
can be effective in reducing clinical inertia, they are not al-
ways effective in improving metabolic control.
Thus, there is a need to design strategies that help
achieve the desired treatment goals that can be simul-
taneously implemented in real-life clinical practice in the
primary care setting and the best way to achieve this
goal is to use the mixed methodology by previously ex-
ploring the patients’ own perspective, in order to design
a proper implementation strategy. Previous studies have
shown that specialised Diabetes Unit improve glycaemic
control [11]. Our main intervention was designed to
evaluate if a local monographic consultation run by pri-
mary healthcare professionals could be effective in the
context of real-world primary healthcare practice for the
management of very poor controlled diabetic patients.
Methods/design
Aims of the study
Following this line of thought, the aim of this study is to
assess whether glycaemic control improves in very
poorly controlled type 2 diabetic patients as a result of
interventions based on treatment intensification and on
an increase in the patients’ adherence to treatment with
a diabetes-targeted clinic specifically held for those
patients.
The hypothesis is that in patients with inadequately
controlled T2DM, a preliminary comprehensive detec-
tion intervention developed based on a monographic
consultation interview and a complex intervention to
improve the self-efficacy of patients could improve the
effectiveness and cost-effectiveness in controlling gly-
caemia and other metabolic and risk factor parameters
compared to the usual practice.
The secondary aims are to determine:
– The percentage of patients who achieve HbA1c levels
of < 7% and < 8%.
– The improvement of lipidaemic control measured by
the mean concentration of low-density lipoprotein cho-
lesterol(LDL-C), non-high density lipoprotein choles-
terol (non-HDL-C), and triglycerides in the
intervention groups relative to the control group.
– Whether the percentage of patients who achieve
target levels of LDL-C, non-HDL-C, and triglycer-
ides recommended by the Catalan Health Institute
guidelines (REGICOR tables) [14] is higher in the
intervention groups than in the control group.
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– Whether the percentage of diabetic patients with
mean systolic blood pressure < 140 mmHg and mean
diastolic blood pressure < 90 mmHg is higher in the
intervention groups than in the control group.
– Whether the adherence to the screening for chronic
complications associated with T2DM, according to the
protocol of the Catalan Health Institute (fundoscopy,
microalbuminuria, examination of the foot: arterial
index and peripheral sensitivity), is better in patients
who have participated in the specialized consultation
unit than in the control group.
– Whether the patient’s self-efficacy to implement
changes in risk factors is different in intervention
group 1 (IG-1) than in intervention group 2 (IG-2).
– Whether the direct health costs of T2DM patients
who participated in the monographic consultation
are different from those in the control group.
– The impact on satisfaction and quality of life of
patients.
– Whether the improvement in the control of
behavioural cardiovascular risk factors (smoking
and exercise) is better in the intervention than
in the control groups.
– The improvement in the adequacy and intensification
of treatment (clinical inertia).
Study design
A mixed method study will be carried out, which will
compare poorly controlled T2DM patients (poor gly-
caemic control was defined as an HbA1c value > 9% in
the last test performed in the 12months prior to study
inclusion), treated with two different comprehensive ap-
proaches with a control group receiving only usual clin-
ical care. The mixed methodology for the development
of complex interventions composed of two phases: a first
phase consisting of a qualitative study carried out
through personal interviews with patients and profes-
sionals, and a second quantitative phase that will corres-
pond to the execution of the clinical trial and in which
the findings of the first phase will be applied.
We designed this study considering that the interven-
tion group 2 will be the control group for Intervention
group 1, where the specific monographic consultation is
implemented. Group Intervention 1 includes the main
intervention for which we will test the effectiveness to
improve glycaemic control. In parallel to Intervention
group 2, we decided to include an additional comparison
group consisting of type 2 diabetic subjects attending
primary care centres managed by our institution in our
region, with subjects selected according to the same
study criteria. To select this latter group, we describe the
use of the Sistema d´Informació per al Desenvolupament
de la investigació en Atenció Primària (SIDIAP) data-
base, which contains anonymised electronic health
records of patients attended at primary care centers of the
same health care districts not participating in the study.
This study is non-randomized because it would be dif-
ficult give a different treatment to an individual in the
same primary care center treated by the same profes-
sional without it affecting the outcome in the standard
care arm of the study.
Study setting
This mixed method study will be conducted in primary
care settings in 3 different health care territories of the
Catalan Health Institute (Lleida, Barcelona, and Girona).
Each basic health care area will be selected with similar
characteristics and will be organized into the interven-
tion group 1 (IG-1), the intervention group 2 (IG-2), and
a control group.
Characteristics of participants
The inclusion criteria include the following: T2DM of
more than one year of disease duration, age between 30
and 80 years, HbA1c > 9% in the last test performed in
the 12months prior to study inclusion, with no change
in antidiabetic treatment within the previous 3months.
The changes in the dose of a drug in the antidiabetic
treatment will be not considered as exclusion criteria.
The exclusion criteria include the following: T2DM
controlled by endocrinologist at the moment of inclu-
sion, systemic glucocorticoid treatment (ATC code:
H02AB) or orlistat treatment (ATC code: A08AB01)
(chronic or during the two months prior to inclusion),
estimated life expectancy < 2 years, active treatment for
malignancy (other than basal cell cancer or squamous
cell skin cancer), serious mental disorders (psychosis, bi-
polar affective disorder, severe depressive episode with
psychotic symptoms), class III or IV (New York Heart
Association functional classification) heart failure
(ICD-10: I50), dementia, renal transplantation or current
dialysis treatment, history of drug and/or alcohol abuse
(ICD-10: F10-F14), pregnancy or lactation, treatment
with immunosuppressive drugs, haemoglobinopathies
(ICD-10: D58.2), or chronic anaemia, body mass index
(BMI) > 45 kg/m2, or any conditions that the investigator
considered could prevent the patient from completing
the study.
Study phases
The INTEGRA study is divided into two distinct phases.
Phase 1 is a qualitative research study, which is aimed at
identifying viable strategies to overcome barriers to
treatment; these strategies have been included in the
intervention study (phase 2). Phase 2 is a controlled,
non-randomized, interventional, pragmatic study that in-
volves primary care centres in 3 regions in Catalonia
(Lleida, Girona and Barcelona).
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Phase 1: Qualitative study
Design A qualitative study with a phenomenological ap-
proach was conducted to identify the barriers and facili-
tators for the management of poorly controlled T2DM
patients. This approach was taken in order to identify
psychosocial factors influencing glycaemic control.
Briefly, we collected information on the patient’s percep-
tion on the communication of the diagnosis, cognitive
representation of the disease (knowledge, cause, symp-
toms, duration, consequences and control of the dis-
ease), emotions associated with the disease (e.g., fears or
worries about the future), and their cognitive and emo-
tional attitudes regarding strategies to control diabetes
(diet, physical activity, and pharmacological activity). Fi-
nally, patients described their perceived relationship with
the health-care professionals and gave their input re-
garding the design of the INTEGRA study (e.g., visit
schedule or use of information and communication
technologies). The results of this phase of the study were
used to draw recommendations and to design strategies
in order to optimize the patient’s adherence and disease
control during the intervention phase of the INTEGRA
study. Thus, other components that may be needed for
the intervention, such as the use of Information and
Communication Technologies like internet platforms or
mobile applications, was also determined.
Recruitment strategies and participants At each pri-
mary care centre, a liaison was selected to facilitate the
communication between the centre and the research
team. One member of the research team contacted the
liaison at each primary care centre. These liaisons, to-
gether with the primary care professionals, identified the
patients who meet the criteria of poor glycaemic control
and contacted the potential participants.
Sampling The sampling for the study was opportunistic
[15]. Although not a theoretical sample, it was taken into
account the following variables: gender, age, years of
progression of T2DM, and type of treatment (oral anti-
diabetics, insulin, or a combination).
Techniques for generating information A psychologist
carried out 8 to 10 semi-structured individual interviews
in each Primary Health Care Centre. This interview
technique is especially useful when it is important to
collect the subjective opinions of societal actors, and be-
comes even more valuable when wanting to explore di-
verse points of view that represent the different attitudes
that might exist regarding the subject of investigation
[16]. The interviews were audio-recorded and subse-
quently transcribed systematically and verbatim.
Analysis A thematic content analysis was performed
based on the information obtained from the interviews
[17]. The data was analysed in the following manner:
after successive readings of the transcribed interviews
[18], the researchers attained some pre-analytical insight
into the data. Next, four researchers conducted the follow-
ing analytical steps: (a) identification of the relevant sub-
jects and texts; (b) fragmentation of the text into units of
meaning; (c) text codification with a mixed strategy:
Leventhal model and emerging codes from the data; (d)
creation of categories by grouping the codes based on the
criterion of similarity; (e) analysis of each category; and (f)
elaboration of a new text with the results. These results
were subsequently discussed by the research team mem-
bers until a consensus was reached (triangulation).
The results of the qualitative study have been pub-
lished recently [19].
Phase 2: Interventional study
Design A controlled, non-randomized interventional
study that involves primary care centres of 3 health care
districts in Catalonia (Lleida, Girona, and Barcelona).
Participants The participants are T2DM patients with
poor glycaemic control that meet all the inclusion cri-
teria and sign the informed consent.
Inclusion criteria for primary health care Centres
The participating Primary Care centres must meet the
following criteria to be eligible: I) experience of more
than 5 years using the eCAP™ programme (electronic
clinical records of Primary Care Centres in Catalonia) to
optimize the use of the software as a source of informa-
tion and intervention (warnings, alerts, etc.); II) centres
with more than 10 general practitioners, to obtain a
large number of study subjects; III) centres belonging to
different health care areas, to increase external validity
of the study; and IV) acceptance by the majority of pro-
fessionals in the centre.
Intervention design In each basic health area, two
intervention groups and one control group were included.
Two different interventions focused on treatment intensi-
fication, namely reducing inertia by professionals and re-
ducing the possible barriers to treatment adherence have
been implemented, one in each intervention group. In
order to reduce inertia by primary care professionals, to
get closer to the objectives of health control, and to allow
reproducibility in the current context of primary care cen-
ters, the intervention was carried out through multiple in-
tegrated strategies. To improve the intervention
replicability, the Template for Intervention Description
and Replication guide was followed [20]. Each health care
district has a contact in a hospital with a Department of
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Endocrinology who provides specialized support for pro-
fessionals if needed.
Intervention group 1 (IG-1)
Intervention 1 consists of a comprehensive strategy with
the following components:
– A specialized consultation carried out by a general
practitioner and a nurse that will provide the
participant with a complete assessment of their case,
and a series of recommendations will be set for case
management, together (only if required) with the
specialized team from Endocrinology and Nutrition
using a telematics communication system. The
strategy recommendation includes management
measures aimed at optimizing blood glucose, blood
pressure, lipid profile, and other cardiovascular risk
factors, as well as the detection of diabetes-
associated complications following the guidelines of
the Catalan Health Institute [21] and the guidance
document of the Department of Health of the local
government (Generalitat de Catalunya) [22].
– Basic training in clinical practice guidelines: consulting
professionals will participate in workshops related to
clinical practice guidelines, thus broadening the
professionals’ knowledge base with regard to
diabetes by providing them with an increased
degree of autonomy in diabetes case management.
– Training of professionals in coaching: all
professionals in the primary care centres will
participate in a 7-h training programme for coaching
to be able to impart practical theoretical content on
the following subjects: strategies for active listening;
strategies for communication without value
judgement; support strategies to develop self-
management skills for diabetes, hypertension, and
hyperlipidaemia; strategies to provide social and
emotional support; strategies to motivate lifestyle
changes; strategies for medication adherence; and
strategies to access community resources.
– The professionals will attend a 2-h training
programme to update their training for reviewing
the practical cases discussed in consultation using a
coaching strategy point of view.
– Interventions based on patients’ SMS phone
messages (sending a message 1 time / week during
the first three months) to promote the change in
behaviour and to maintain healthy lifestyle changes
to improve diabetes control.
Intervention group 2 (IG-2)
Patients allocated to the IG-2 will receive the same per-
sonalized intervention described for the IG-1, without
the monographic consultation (Fig. 1).
Control group
The control group will consist of a randomized selection
of patients who meet the inclusion criteria and have the
same sociodemographic and clinical characteristics as
the patients from the intervention groups, including the
three participating health care districts. Patients allo-
cated in this group will receive routine clinical care with
the usual control by the family doctor and nurse accord-
ing to the current Catalan Health Institute protocol. The
data of patients in the control group will be obtained
from the electronic medical record (SIDIAP) database
[23]. The inclusion period for the control group will be
from 9 December 2015 (the date when the first patient
entered the study) until 31 October 2017 (end of the
recruiting period). Data on diabetic status, glycaemia
and all other study variables that were recorded in the
electronic health records for patients in the intervention
groups will be extracted from the SIDIAP database for
12 months for each patient. Participants will be followed
up until they experience the outcomes of interest, die,
leave the SIDIAP database (e.g., change of address) or
complete the follow-up (31 October 2018). If the inter-
vention groups reach the study sample earlier than 31
July 2017, the data for the control group will be followed
until 12 months from the date when the last patient
would be enrolled in the intervention group.
Study variables The variables are collected at different
time-points during the study (Table 1). These include:
sociodemographic variables (age, sex), anthropometric
variables (height, weight, BMI, blood pressure), clinical
variables (drugs and dosages), smoking habits (smoking,
non-smoker, ex-smoker), presence of multiple disorders
(Clinical Risk Group and identified in the computerized
patient clinical history and the number of health prob-
lems as a proxy asset of multi-morbidity), presence of
microvascular complications (diabetic retinopathy, dia-
betic nephropathy, and diabetic neuropathy), presence of
macrovascular complications (ischaemic heart disease,
stroke, peripheral vascular disease, and heart failure), la-
boratory variables according to the standard procedures
of the laboratory of reference (HbA1c, blood count,
renal function- creatinine, glomerular filtration rate,
urinary excretion of albumin), liver function (Alanine
Aminotrasferase (ALT), Aspartate Aminotransferase
(AST), alkaline phosphatase, Gammaglutamil transferase
(GGT)), lipid profile (total cholesterol, HDL-C, triglycer-
ides, LDL-C, and non-HDL-C), and episodes of severe
hypoglycaemia (episodes of hypoglycaemia that require
the intervention of a third party for recovery will be
recorded).
Variables related to healthcare costs are also collected
and include the costs derived from the medication used
(cost per patient per month of medication prescribed
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according to prices set by the Health Ministry), labora-
tory tests used (based on prices listed in the Catalan
Health Institute service portfolio), supplementary tests,
professional costs (the cost of patient visits), cost derived
from the referrals to specialists, use of the emergency
department, outpatient and hospital admissions, tempor-
ary disability, and consumption of testing strips for
measuring blood glucose.
The INTEGRA study includes variables evaluated
using specific questionnaires:
– Physical activity: this is assessed using the Spanish
version of the Brief Physical Activity Assessment
Tool questionnaire [24]. It contains two questions
that are scored on a scale from 0 to 4. The sum of
the scores of both questions are classified
as follows: ≥ 4 total score = “sufficiently” active
(encourage the patient to continue their activity) or
0 to 3 total score = “insufficiently” active (encourage
the patient to increase their activity).
– Patient treatment satisfaction: this is assessed using
the Diabetes Treatment Satisfaction Questionnaire
(DTSQ) [25] in both the “status” and “change”
versions validated for Spanish patients. It comprises
8 sections, each of which is rated on a scale from 0
to 6 points. The score of satisfaction with treatment
is the sum of the 6 sections of the questionnaire,
which can range from very satisfied (36 points) to
very dissatisfied (0 points). The remaining 2 sections
measure the perceived frequency of hyperglycaemia
and hypoglycaemia from 0 (never perceived) to 6
(perceived most of the time), and they are scored
separately.
– Quality of life: this is measured using the validated
Spanish version of the Diabetes Quality of Life
Questionnaire (ESDQoL) [26], which consists of 21
items, of which 19 relate to specific life domains.
The items are scored on a 5-point scale of impact.
The effects of diabetes on each of the domains are
weighted according to their importance to the
quality of life of patients, and the weighted average
impact is obtained.
– Satisfaction of the health professionals before and
after the interventions proposed in the study is
assessed by a questionnaire divided into 4 sections;
the first three assess aspects of organization, content,
and structure, and the fourth refer to the overall
assessment.
– Clinical inertia is evaluated through the questionnaire
created by the RedGEDAPS [27]. This questionnaire
consists of 5 questions with two possible answers (yes
or no) that professionals should answer in each visit
when HbA1c > 9%.
– Self-management of the disease is evaluated by the
Spanish validated version of the Patient Activation
Measure questionnaire [28]. This questionnaire
evaluates patients’ ability to play an active role in their
health care by assessing knowledge, skills, confidence,
and behaviours. It consists of 13 questions in which
there are 5 possible response options (strongly disagree,
Centres enrolment         
Phase 1- Qualitative study                              
8-10 patients/professionals 
Semi-structured interviews          Centres of three
geographical areas of                                                                                                        
of Catalunya
Phase 2- Clinical trial
Intervention group 1+   n=72
(Follow up:  0, 3, 6, 12 m)
Intervention group 2++   n=72
(Follow up: 0, 3, 12 m)
Lleida 
Barcelona 
Girona  
Intervention group 1+   n=72
(Follow up:  0, 3, 6, 12 m)
Intervention group 2++   n=72
(Follow up: 0, 3, 12 m)
Intervention group 1+   n=72
(Follow up:  0, 3, 6, 12 m)
Intervention group 2++   n=72
(Follow up: 0, 3, 12 m)
Control group n= 216
Fig. 1 Study flow chart. *Control group: usual clinical care with the usual control by the family doctor and nurse according to the current CPG
protocol. +Intervention 1: Usual clinical care with the usual control + Monographic consultation + Basic training in clinical practice guidelines +
Training in coaching + 2-h training program to update the coaching strategy + Intervention based on patients SMS phone messages. ++Intervention
2: Usual clinical care with the usual control + Basic training in clinical practice guidelines + Training in coaching + 2-h training program to update the
coaching strategy + Intervention based on patients SMS phone messages. m: months
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disagree, agree, strongly agree, N/P). The scores range
in value from 38.6 to 53.0 (on a 0–100 theoretical point
scale).
Data collection
In the intervention groups (groups 1 and 2), sociodemo-
graphic, anthropometric, clinical, and laboratory vari-
ables are obtained from the clinical history and
anamnesis of the subjects. The data obtained through
the questionnaires are collected during the clinic visit
according to the subjects’ responses. The variables re-
lated to health care costs are obtained from the SIDIAP
database. In the control groups, all data will be obtained
from the SIDIAP database.
For both groups, variables related to data are collected
as described in Table 1 in the Electronic Case Report
Form (e-CRF), specifically designed for the purpose of
the study.
The consultation with the specialists is carried out in
addition to any others that are deemed necessary, and
the number and frequency of visits is derived from the
interventions proposed to the patients (pharmacological
and non-pharmacological).
Evaluation of the effectiveness between the two
intervention groups
The e-CRF has been used to perform an evaluation at
baseline, 3, 6, and 12months. Secondary aims, such as
patient’s self-efficacy to implement changes in risk fac-
tors, the direct health costs of T2DM patients, and the
impact on satisfaction and quality of life of patients, is
assessed using the e-CRF data, and the other informa-
tion will be obtained from SIDIAP database.
Table 1 Study timeline, variables and procedures
IG-1 and IG-2 Control group
Data collected Assessment (months) Source Assessment Source
0 3 6 12 Month 0 & Month 12
Inclusion/Exclusion criteria 1 + 2 1 + 2 1 1 + 2 e-CRF § SIDIAP
Sociodemographic variables and comorbidities:
1. Age, height, gender, weight, BMI, duration of T2DM, medication
(active component and dose), etc....
2. Pluripathology, clinical risk group
1 + 2 1 1 1 + 2 eCAP § SIDIAP
Main variable: HbA1c 1 + 2 1 1 1 + 2 e-CRF
eCAP
§ SIDIAP
Lipid profile and other laboratory variables:
Total cholesterol, HDL, LDL, triglycerides, non-HDL, urea, creatinine,
glomerular filtration rate, urine albumin, AST, ALT, FA, GGT.
Systolic and diastolic blood pressure
1 + 2 1 1 1 + 2 eCAP
e-CRF
§ SIDIAP
Smoking habit 1 + 2 1 1 1 + 2 eCAP
e-CRF
§ SIDIAP
Sedentary lifestyle 1 + 2 1 + 2 1 1 + 2 e-CRF
Detection of macrovascular complications
Ischaemic heart disease, stroke, peripheral artery disease, heart failure
1 + 2 1 1 1 + 2 eCAP
e-CRF
§ SIDIAP
Chronic microvascular complications detection
Diabetic retinopathy, diabetic nephropathy (albuminuria, renal failure),
diabetic neuropathy.
1 + 2 1 1 1 + 2 eCAP
e-CRF
§ SIDIAP
Costs:
Cost of medication, laboratory tests, additional tests, cost of staff
(visits), referrals, IT
1 + 2 1 + 2 eCAP
e-CRF
§ SIDIAP
Costs:
Urgent care, outpatient and hospital admissions
1 + 2 1 + 2 e-CRF
Satisfaction and quality of life of patients DTSQ / ESDQoL 1 + 2 1 1 + 2 e-CRF
Professional Satisfaction
Specific Questionnaire
1 + 2 e-CRF
intensification/treatment adherence 1 + 2 1 1 + 2 e-CRF
Occurrence of severe hypoglycaemia episodes 1 + 2 1 1 1 + 2 e-CRF SIDIAP
“Patient Activation Measure” questionnaire (instrument for
disease self-evaluation)
1 + 2 1 + 2 1 + 2 e-CRF
For the IG-1 (monographic + training of professionals + additional measures originated in phase 1), clinic visits will be carried out at baseline, 3, 6, and 12 months. For
the IG-2 (training of professionals + additional measures originated in phase 1), clinic visits will be carried out at the time of inclusion (month 0), 3, and 12 months
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Evaluation of the effectiveness in the three study groups
Data at baseline and at 12 months of the population of
all three types of learning centres that meet the defined
criteria for inclusion and exclusion will be compared.
Criteria will be adequately defined using the ICD-10
codes, thoroughly specifying the temporary windows
of the accepted values. Only the outcomes that in-
clude SIDIAP variables (as indicated in the Table 1)
will be able to be evaluated; even those that are in
the e-CRD will not be able to be assessed. This evalu-
ation of effectiveness will be performed in two pos-
sible ways: i) following the patients who meet the
inclusion criteria in 2015 until the end of the study
in 2018 (cohort study), or ii) a cross-sectional study
in 2015 and another in 2018.
Sample size calculation
The sample size was calculated using the GRANMO
v.7.12 (IMIM, Barcelona) programme. Considering an
alpha risk of 0.05 and a beta risk of less than 0.2 in a bi-
lateral contrast, it was necessary to include 72 patients
in each group (intervention and control) to detect a dif-
ference equal to or greater than 1% of HbA1c [5] be-
tween the two groups. A common standard deviation of
1.46 [6] and a loss rate to follow up of 20% were
assumed.
Considering that each physician/nurse that makes up
the Basic Care Unit will coordinate their diabetic pa-
tients, a correction may be made due to a possible con-
tamination in the analysis between individuals by
assigning each Primary Care Team to intervention or
control groups and taking into account the design effect.
According to a study performed by our research group
[16], we estimated that each GP would have 15 potential
candidate patients with HbA1c > 9%. Assuming that the
intra-class correlation coefficient for Primary Care is
0.05 [29], resulting in a 1.7 design effect, the required
sample size will be 42 * 1.7 = 72 individuals in each
group.
Each control or intervention group consists of 3 basic
health areas, one in each geographical area, each with a
mean of 10 BCUs and 15 individuals per basic care unit.
Thus, the sample finally calculated to obtain statistical
significance was 72 subjects per centre, leading to a total
of 648 study subjects.
First patient enrolled in the study INTEGRA on 09/
12/2015.
Statistical analysis plan
For data analysis, the IG-1, the IG-2, and the control
group will be compared. All analyses will be carried out
using bilateral tests with a nominal significance level of
0.05. However, if the comparisons obtain a p-value of
less than 0.10, they will also be discussed as indicative of
trends. Initially, basal characteristics of all groups will be
evaluated to establish homogeneity in age, socio-demo-
graphic, comorbidities, laboratory parameters, concomi-
tant medication and diabetes complications. An initial,
descriptive comparison between groups of all variables
will be performed to evaluate their baseline balance.
Statistical significance will be assessed by the chi-square
or t-test between the groups. Exploratory analyses will
be applied when necessary.
The main variable is set as the difference in mean
HbA1c values between the final visit and baseline. The
difference will be evaluated in terms of the evolution of
HbA1c as contrasted between groups by paired
t-Student, or if the assumption of normality is not met
for the right non-parametric.
If differences in the characteristics of the patients in
each group are observed in the descriptive section of the
study, a linear regression of the main variable (parameter
evolution during the study) will be adjusted. This linear
regression adjusted for the variables identified in the de-
scriptive section, or the ability to adjust the model by
setting a propensity score, will be evaluated. For all
models, the distribution of waste will be studied, as well
as the coefficient of determination (R2), to check for the
correct setting.
As was done in Vinagre et al. [4], a subgroup analysis
will be performed by a) gender (male / female), b) age: <
age 65 / ≥ 65, and c) according to HbA1c control levels
(< 10% / ≥ 10%).
We will determine the prevalence of patients who
achieved a concentration of HbA1c of less than 7% at
the end of the study. A categorical variable (No, Yes) will
be calculated. The analysis of a significant decrease in
HbA1c will be carried out using a logistic regression
analysis adjusting by the effect of the study groups (as
dummy variable) and the main factors previously deter-
mined to be associated with the target of 7% (in a previ-
ous descriptive analysis or adjustment by the propensity
score). The power of discrimination (C statistic and ROC
curve) and calibration (Hosmer & Lemeshow test) for
the final models will be studied. The software we will
use for analysis of the data will be R Core Team (2014).
R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna,
Austria (http://www.R-project.org/).
Data Management
The researchers who collaborate in each of the primary
care centres are responsible for the accurate, complete,
and reliable collection of all data. An e-CRF has been cre-
ated for the study, and a data extraction from patient’s
medical history will also be performed. An expert, inde-
pendent professional from the Primary Care Centres is re-
sponsible for periodically monitoring to corroborate the
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reliability of the data entered in the e-CRF with respect to
electronic health records. The detailed description of the
study-monitoring plan is shown in the Additional file 1.
Ethics and dissemination
The study is conducted according to the Helsinki Dec-
laration and Good Clinical Practice guidelines. The study
protocol was approved by the Ethics Committee of
IDIAP Jordi Gol, Institute of Research in Primary Health
Care. Trial Registration Number: P14/129.
Reporting of this trial will adhere to the most relevant
and up-to-date CONSORT statement [30] and its rele-
vant extensions [31]. The results from this study will be
published regardless of the outcomes.
Confidentiality and anonymity of the data is en-
sured according to Law 15/1999 of data confidential-
ity, both in the implementation phase of the project
and in the resulting presentations and/or publications.
Individual data will be codified to ensure anonymity.
Only researchers and monitors will have access to the
data.
Discussion
According to the SIDIAP database, which contains all
the data entered into the eCAP, the database used in
Catalan Health Institute, 79.6% of the patients have
HbA1c values ≤8%, and the proportion of patients with
fair control (HbA1c ≤7%) is 56.1% [4].
The INTEGRA study defines potential pragmatic new
strategies to improve metabolic control in patients with
very poorly controlled T2DM in the primary care setting
that, if demonstrated to be effective, could be imple-
mented by professionals in their real-life practices at
ICS. The research team agreed to define poorly con-
trolled T2DM patients as those who had HbA1c levels
≥9%. This is because at the time of the protocol writing,
local and international guidelines were recommending
the initiation of insulin therapy in type 2 diabetes when
HbA1c levels were between 8.5 and 10% [32, 33]. Due to
this the lack of agreement, the ≥9% cut-off was chosen
in accordance with the AACE Comprehensive Diabetes
Management Algorithm 2013 [34], which is actually a
value in between all recommendations. Moreover, our
population characteristics and primary health care pat-
terns of treatment were taken in account. Indeed, those
subjects with HbA1c levels > 9% are usually the ones
that most often need to be treated with insulin, but this
therapy is frequently delayed or not even started by
some general practitioners in our primary health-care
centres [4]. Some studies report that a multifactorial tar-
get intervention used for the management of T2DM is
effective and feasible in clinical practice. An intensive
intervention strategy delivered at the clinical level is as-
sociated with a significant and durable improvement in
HbA1c and major cardiovascular risk factors, well beyond
that achieved with the usual practices [35]. Some studies
describe that patient-centred care is more valuable when
targeted to patients with HbA1c > 8.5%. Patient-centred
care was most effective and cost-effective in those pa-
tients, resulting in more improved glycaemic and meta-
bolic control but also improving quality-adjusted life years
and costs of associated complications [36].
In addition to the implementation of methodological
tools proposed by the INTEGRA study, identifying the
factors that hinder the metabolic control of these pa-
tients will allow us to define new strategies for improv-
ing patient care, especially for poorly controlled patients.
These strategies include improving adherence to treat-
ment proposed by primary care professionals, as well as
eliminating the clinical inertia of these professionals
treating patients who have difficulty achieving good gly-
caemic control targets.
There are some limitations in this study. It is well
known that patients who voluntarily participate in re-
search projects tend to be more motivated, which can be
a common bias in all clinical trials where patients sign
an informed consent. In the present study, we aim to re-
cruit a large group of patients in each centre.
The external validity of the study will be determined
by the ability to recruit as many candidates as possible
because the profiles of the patients included in the study
show characteristics of low participation in clinical trials
and less adherence to treatment recommendations. An
important strength of the study is that it will follow the
CONSORT Statement for the reporting and publishing
of clinical trials. Another strength of the study is that
the Medical Research Council’s methodology allows for
the adaptation of the complex intervention’s compo-
nents to the needs of participants based on the results of
the qualitative study, and therefore an easier implemen-
tation in Primary care centres.
Targeting interventions at the high-risk population
may allow for better use of resources, reduction of cost,
and reduction of side effects by avoiding unnecessary
use of medications.
Additional file
Additional file 1: Monitoring plan. The monitoring plan include process
for monitoring activities of the study, definition of the key information
concerning the realization of the study, the verification of data sources,
essential documents of the study. (PDF 294 kb)
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